PMID- 33344912
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211016
IS  - 2575-9108 (Electronic)
IS  - 2575-9108 (Linking)
VI  - 3
IP  - 6
DP  - 2020 Dec 11
TI  - Defusing SARS-CoV-2: Emergency Brakes in a Vaccine Failure Scenario.
PG  - 1425-1426
LID - 10.1021/acsptsci.0c00152 [doi]
AB  - Deactivation of primed SARS-CoV-2 prior to cell entry constitutes an emergency 
      brake in COVID-19 infection if vaccine-induced antibodies fail to block 
      recognition of the human angiotensin-converting enzyme 2 (hACE2) receptor. The 
      timing and locus for the therapeutic intervention are dictated by the cell entry 
      mechanism and by the selective advantage of the dominant D614G mutation.
CI  - (c) 2020 American Chemical Society.
FAU - Fernandez, Ariel
AU  - Fernandez A
AD  - Daruma Institute for AI in Pharmaceutical Research, AF Innovation Pharma 
      Consultancy, 4000 Pemberton Court, Winston-Salem, North Carolina 27106, United 
      States.
AD  - CONICET, National Research Council for Science and Technology, Buenos Aires 1033, 
      Argentina.
LA  - eng
PT  - Journal Article
DEP - 20201015
PL  - United States
TA  - ACS Pharmacol Transl Sci
JT  - ACS pharmacology & translational science
JID - 101721411
PMC - PMC7737315
COIS- The author declares no competing financial interest.
EDAT- 2020/12/22 06:00
MHDA- 2020/12/22 06:01
PMCR- 2021/10/15
CRDT- 2020/12/21 06:10
PHST- 2020/09/28 00:00 [received]
PHST- 2020/12/21 06:10 [entrez]
PHST- 2020/12/22 06:00 [pubmed]
PHST- 2020/12/22 06:01 [medline]
PHST- 2021/10/15 00:00 [pmc-release]
AID - 10.1021/acsptsci.0c00152 [doi]
PST - epublish
SO  - ACS Pharmacol Transl Sci. 2020 Oct 15;3(6):1425-1426. doi: 
      10.1021/acsptsci.0c00152. eCollection 2020 Dec 11.